NasdaqGM - Nasdaq Real Time Price USD

Aspire Biopharma Holdings, Inc. (ASBP)

0.3655

-0.0145

(-3.82%)

At close: June 13 at 4:00:00 PM EDT

0.3669

+0.00

+(0.38%)

After hours: June 13 at 6:19:46 PM EDT

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025 Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board ...

ACCESS Newswire 4 days ago

ASBP
-3.82%

ASBPW
Aspire Biopharma provides development update on BUZZ BOMB supplement

Aspire Biopharma (ASBP) announced the brand name BUZZ BOMB and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential. Aspire has commenced initial production of BUZZ BOMB, its single serving pre-workout caffeine supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery technology

TipRanks 16 days ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market Initial production has commenced with six flavor options Expanded pre-launch consumer testing planned for Q2 ...

ACCESS Newswire 17 days ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Trial marks key milestone in driving pipeline progress Phase 1 trial scheduled for completion mid-June 2025 Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback ...

ACCESS Newswire 25 days ago

ASBP
-3.82%

ASBPW
Sidoti Events, LLC's Virtual May Micro-Cap Conference

NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 21-22, ...

ACCESS Newswire 25 days ago

LFWD

CMCXF

HFFG
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, ...

ACCESS Newswire last month

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted ...

ACCESS Newswire last month

ASBP
-3.82%

ASBPW
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire last month

BNZI

BNZIW

SEVCF
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, ...

ACCESS Newswire last month

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Plans to conduct consumer and safety testing during second quarter 2025 Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production Single dose pre-workout supplement expected to be available ...

ACCESS Newswire 2 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

One clinical trial site activated Patient enrollment expected in April Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product Aspire anticipates releasing initial clinical data from trial at ...

ACCESS Newswire 2 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire intends to request "fast track" approval on FDA ...

ACCESS Newswire 2 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update ...

ACCESS Newswire 3 months ago

ASBP
-3.82%

ASBPW
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual technology, designed to rapidly deliver therapeutics while bypassing the gastrointestinal tract and liver. SmallCaps Daily sat down with CEO Kraig Higginson to learn more about

Newsfile 3 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market Desert Stream Inc., a well-established nutritional and supplement manufacturer of caffeine-based products, engaged for sourcing of ...

ACCESS Newswire 3 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete Test results support the next development step with Phase 1clinical trial expected to commence in April Provides Summary of Expected ...

ACCESS Newswire 3 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced ...

ACCESS Newswire 3 months ago

ASBP
-3.82%

ASBPW
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, nutraceuticals, and supplements Aspire has multiple product ...

ACCESS Newswire 3 months ago

ASBP
-3.82%

PWUP

PWUPU

Performance Overview

Return	ASBP	S&P 500 (^GSPC)
YTD	-96.82%	+1.62%
1-Year	-96.75%	+10.00%
3-Year	-96.34%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma provides development update on BUZZ BOMB supplement

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

Performance Overview